Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Atherosclerosis is aggravated by iron overload and ameliorated by dietary and pharmacological iron restriction.

Vinchi F, Porto G, Simmelbauer A, Altamura S, Passos ST, Garbowski M, Silva AMN, Spaich S, Seide SE, Sparla R, Hentze MW, Muckenthaler MU.

Eur Heart J. 2019 Mar 20. pii: ehz112. doi: 10.1093/eurheartj/ehz112. [Epub ahead of print]

PMID:
30903157
2.

Non-transferrin-bound iron and hepatic dysfunction in African dietary iron overload.

McNamara L, MacPhail AP, Mandishona E, Bloom P, Paterson AC, Rouault TA, Gordeuk VR.

J Gastroenterol Hepatol. 1999 Feb;14(2):126-32.

PMID:
10029292
3.

[Non-transferrin-bound iron: a promising biomarker in iron overload disorders].

Maas RP, Voets PJ, de Swart L, Swinkels DW.

Ned Tijdschr Geneeskd. 2013;157(49):A6258. Review. Dutch.

PMID:
24299624
4.

Endothelial activation and induction of monocyte adhesion by nontransferrin-bound iron present in human sera.

Kartikasari AE, Georgiou NA, Visseren FL, van Kats-Renaud H, van Asbeck BS, Marx JJ.

FASEB J. 2006 Feb;20(2):353-5. Epub 2005 Dec 20.

PMID:
16368718
5.

Transport of Non-Transferrin Bound Iron to the Brain: Implications for Alzheimer's Disease.

Tripathi AK, Karmakar S, Asthana A, Ashok A, Desai V, Baksi S, Singh N.

J Alzheimers Dis. 2017;58(4):1109-1119. doi: 10.3233/JAD-170097.

6.

Chronic iron overload in rats increases vascular reactivity by increasing oxidative stress and reducing nitric oxide bioavailability.

Marques VB, Nascimento TB, Ribeiro RF Jr, Broseghini-Filho GB, Rossi EM, Graceli JB, dos Santos L.

Life Sci. 2015 Dec 15;143:89-97. doi: 10.1016/j.lfs.2015.10.034. Epub 2015 Oct 30.

PMID:
26523985
7.

Can iron chelators influence the progression of atherosclerosis?

Marx JJ, Kartikasari AE, Georgiou NA.

Hemoglobin. 2008;32(1-2):123-34. doi: 10.1080/03630260701726871. Review.

PMID:
18274990
8.

Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

Evans P, Kayyali R, Hider RC, Eccleston J, Porter JB.

Transl Res. 2010 Aug;156(2):55-67. doi: 10.1016/j.trsl.2010.05.002. Epub 2010 May 27.

9.

Non-transferrin-bound iron is associated with biomarkers of oxidative stress, inflammation and endothelial dysfunction in type 2 diabetes.

Aljwaid H, White DL, Collard KJ, Moody AJ, Pinkney JH.

J Diabetes Complications. 2015 Sep-Oct;29(7):943-9. doi: 10.1016/j.jdiacomp.2015.05.017. Epub 2015 Jun 3.

PMID:
26104728
10.

Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving intravenous iron dextran or iron sucrose.

Pai AB, Conner T, McQuade CR, Olp J, Hicks P.

Biometals. 2011 Aug;24(4):603-13. doi: 10.1007/s10534-011-9409-6. Epub 2011 Jan 13.

PMID:
21229380
11.

Copper chelation by tetrathiomolybdate inhibits vascular inflammation and atherosclerotic lesion development in apolipoprotein E-deficient mice.

Wei H, Zhang WJ, McMillen TS, Leboeuf RC, Frei B.

Atherosclerosis. 2012 Aug;223(2):306-13. doi: 10.1016/j.atherosclerosis.2012.06.013. Epub 2012 Jun 16.

12.

The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation.

Breuer W, Ronson A, Slotki IN, Abramov A, Hershko C, Cabantchik ZI.

Blood. 2000 May 1;95(9):2975-82.

13.

Physiological implications of NTBI uptake by T lymphocytes.

Pinto JP, Arezes J, Dias V, Oliveira S, Vieira I, Costa M, Vos M, Carlsson A, Rikers Y, Rangel M, Porto G.

Front Pharmacol. 2014 Feb 26;5:24. doi: 10.3389/fphar.2014.00024. eCollection 2014.

14.

Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1.

al-Refaie FN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV.

Br J Haematol. 1992 Oct;82(2):431-6.

PMID:
1419825
15.

Non-transferrin-bound iron is present in serum of hereditary haemochromatosis heterozygotes.

de Valk B, Addicks MA, Gosriwatana I, Lu S, Hider RC, Marx JJ.

Eur J Clin Invest. 2000 Mar;30(3):248-51.

PMID:
10692002
16.

The Impact of Iron Overload in Acute Leukemia: Chronic Inflammation, But Not the Presence of Nontransferrin Bound Iron is a Determinant of Oxidative Stress.

Olcay L, Serteser M, Kolay M, Balci HF, Yildirim ÜM, Tekgündüz SA, Hazirolan T, Terzi YK.

J Pediatr Hematol Oncol. 2017 Aug;39(6):425-439. doi: 10.1097/MPH.0000000000000867.

PMID:
28731917
17.

Non-transferrin-bound iron assay system utilizing a conventional automated analyzer.

Ito S, Ikuta K, Kato D, Shibusa K, Niizeki N, Tanaka H, Addo L, Toki Y, Hatayama M, Inamura J, Shindo M, Sasaki K, Iizuka N, Fujiya M, Torimoto Y, Kohgo Y.

Clin Chim Acta. 2014 Nov 1;437:129-35. doi: 10.1016/j.cca.2014.07.013. Epub 2014 Jul 27.

PMID:
25072389
18.

Ameliorating Iron Overload in Intestinal Tissue of Adult Male Rats: Quercetin vs Deferoxamine.

El-Sheikh AA, Ameen SH, AbdEl-Fatah SS.

J Toxicol. 2018 Nov 21;2018:8023840. doi: 10.1155/2018/8023840. eCollection 2018.

19.

Iron metabolism in kidney allograft recipients: still a mystery?

Malyszko J, Głowińska I, Malyszko JS, Levin-Iaina N, Koc-Zorawska E, Mysliwiec M.

Transplant Proc. 2011 Oct;43(8):2973-5. doi: 10.1016/j.transproceed.2011.08.055.

PMID:
21996204
20.

Correlates of hepcidin and NTBI according to HFE status in patients referred to a liver centre.

Ryan E, Ryan JD, Russell J, Coughlan B, Tjalsma H, Swinkels DW, Stewart S, Crowe JP.

Acta Haematol. 2015;133(2):155-61. doi: 10.1159/000363490. Epub 2014 Sep 26.

PMID:
25277871

Supplemental Content

Support Center